GYRE THERAPEUTICS, INC.
GYRENasdaq
$6.05
↓ -5.8%Jul 17 close · end-of-day
Price
1Y↓ -18.4%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$552.6M
Enterprise Value
$502.8M
P/E
—
P/S
4.7
P/B
5.5
EV/EBITDA
203.0
PEG
—
FCF Yield
0.6%
Dividend Yield
—
Revenue (TTM)
$117.0M
Net Income (TTM)
-$3.7M
Free Cash Flow (TTM)
$3.1M
Gross Margin
—
Operating Margin
-0.1%
Net Margin
-3.2%
ROE
-3.7%
ROIC
-0.1%
Debt / Equity
—
Net Cash
$49.8M
Return 1Y
-18.1%
Company profile
Gyre Therapeutics is a biopharmaceutical company headquartered in San Diego, CA.
- CEO
- Han Ying
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 40
- Headquarters
- California
- Website
- www.gyretx.com
Earnings
GYRE Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$22.5M↑ +2.1%
Diluted EPS-$0.10—
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $20.9M | $7.3M | $102.3M | $113.5M | $105.8M | $116.6M |
| Gross profit | — | — | $97.5M | $108.8M | $101.9M | — |
| Operating income | -$57.4M | -$87.9M | $9.2M | -$67.2M | $16.2M | $11.5M |
| Net income | -$56.2M | -$87.9M | $4.3M | -$85.5M | $17.9M | $9.9M |
| Diluted EPS | — | -$2.87 | $0.03 | -$1.41 | $0.05 | $0.02 |
| Operating cash flow | -$55.0M | -$83.8M | $10.7M | $25.9M | -$3.6M | $1.0M |
| Free cash flow | — | -$84.6M | $5.7M | $17.4M | -$6.0M | -$180,000.00 |
| Gross margin | — | — | 95.3% | 95.9% | 96.3% | — |
| Operating margin | -273.9% | -1197.8% | 9.0% | -59.3% | 15.3% | 9.9% |
| Net margin | -268.5% | -1198.3% | 4.2% | -75.3% | 16.9% | 8.5% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $25.2M | $25.5M | $27.9M | $22.1M | $26.8M | $30.6M | $37.2M | $22.5M |
| Gross profit | $24.5M | $24.5M | $26.7M | $21.2M | $25.6M | $28.9M | — | — |
| Operating income | $3.2M | $4.2M | $665,000.00 | $2.3M | $2.2M | $6.9M | $118,000.00 | -$9.4M |
| Net income | $4.5M | $2.9M | $569,000.00 | $3.7M | $1.6M | $5.9M | -$1.4M | -$9.9M |
| Diluted EPS | $0.01 | $0.01 | $0.00 | $0.00 | $0.00 | $0.03 | -$0.01 | -$0.10 |
| Operating cash flow | -$5.5M | $1.7M | -$2.8M | -$129,000.00 | $2.1M | $4.7M | -$5.6M | $3.2M |
| Free cash flow | -$6.9M | $1.0M | -$2.8M | -$251,000.00 | $1.8M | $4.0M | -$5.8M | $3.0M |
| Gross margin | 96.9% | 96.2% | 95.8% | 95.9% | 95.7% | 94.7% | — | — |
| Operating margin | 12.7% | 16.6% | 2.4% | 10.3% | 8.1% | 22.7% | 0.3% | -41.5% |
| Net margin | 18.0% | 11.2% | 2.0% | 16.9% | 5.9% | 19.4% | -3.7% | -43.8% |
Company news
Jul 16, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-18 | Ye Weiguo· Chief Operating Officer | Sale | 3,000 | $6.35 | $19,050.00 | filing |
| 2026-06-18 | Ye Weiguo· Chief Operating Officer | Option exercise | 3,000 | $0.75 | $2,250.00 | filing |
| 2026-06-11 | Ye Weiguo· Chief Operating Officer | Sale | 2,800 | $6.17 | $17,276.00 | filing |
| 2026-06-11 | Ye Weiguo· Chief Operating Officer | Option exercise | 2,800 | $0.75 | $2,100.00 | filing |
| 2026-06-10 | Ye Weiguo· Chief Operating Officer | Sale | 6,418 | $6.21 | $39,855.78 | filing |
| 2026-06-10 | Ye Weiguo· Chief Operating Officer | Sale | 5,000 | $6.24 | $31,200.00 | filing |
| 2026-06-10 | Ye Weiguo· Chief Operating Officer | Option exercise | 6,418 | $0.75 | $4,813.50 | filing |
| 2026-06-10 | Ye Weiguo· Chief Operating Officer | Option exercise | 5,000 | $0.75 | $3,750.00 | filing |
| 2026-06-09 | Ye Weiguo· Chief Operating Officer | Sale | 14,500 | $6.14 | $89,030.00 | filing |
| 2026-06-09 | Ye Weiguo· Chief Operating Officer | Sale | 3,000 | $6.15 | $18,450.00 | filing |
| 2026-06-09 | Ye Weiguo· Chief Operating Officer | Option exercise | 14,500 | $0.75 | $10,875.00 | filing |
| 2026-06-09 | Ye Weiguo· Chief Operating Officer | Option exercise | 3,000 | $0.75 | $2,250.00 | filing |
| 2026-06-05 | Ye Weiguo· Chief Operating Officer | Sale | 15,401 | $6.40 | $98,566.40 | filing |
| 2026-06-05 | Ye Weiguo· Chief Operating Officer | Option exercise | 15,401 | $0.75 | $11,550.75 | filing |
| 2026-06-04 | Ye Weiguo· Chief Operating Officer | Sale | 19,575 | $6.13 | $119,994.75 | filing |
| 2026-06-04 | Ye Weiguo· Chief Operating Officer | Option exercise | 19,575 | $0.75 | $14,681.25 | filing |
| 2026-05-26 | Ye Weiguo· Chief Operating Officer | Sale | 4,000 | $6.10 | $24,400.40 | filing |
| 2026-05-26 | Ye Weiguo· Chief Operating Officer | Option exercise | 4,000 | $0.75 | $3,000.00 | filing |
| 2026-05-22 | Ye Weiguo· Chief Operating Officer | Sale | 3,500 | $6.08 | $21,280.00 | filing |
| 2026-05-22 | Ye Weiguo· Chief Operating Officer | Option exercise | 3,500 | $0.75 | $2,625.00 | filing |
| 2026-05-21 | Ye Weiguo· Chief Operating Officer | Sale | 12,820 | $6.15 | $78,843.00 | filing |
| 2026-05-21 | Ye Weiguo· Chief Operating Officer | Option exercise | 12,820 | $0.75 | $9,615.00 | filing |
| 2026-05-20 | Ye Weiguo· Chief Operating Officer | Sale | 9,400 | $6.15 | $57,810.00 | filing |
| 2026-05-20 | Ye Weiguo· Chief Operating Officer | Option exercise | 9,400 | $0.75 | $7,050.00 | filing |
| 2026-05-19 | Ye Weiguo· Chief Operating Officer | Sale | 9,120 | $6.37 | $58,094.40 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.